Showing results (21-30 of 32) with videos related to
Sort By:
Pageof 4
Diabetes Care|December 24, 2005
Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trialLynn E Eberly, Ronald Prineas, Jerome D Cohen, et al.Clinical Chemistry|January 8, 2004
Troponin I in patients without chest painDetlef Ritter, Paul A Lee, James F Taylor, et al.Journal of Clinical Lipidology|December 10, 2013
Effect of health information technology interventions on lipid management in clinical practice: a systematic review of randomized controlled trialsKaren E Aspry, Roy Furman, Dean G Karalis, et al.Journal of Clinical Lipidology|September 1, 2016
Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) studyDean G Karalis, Robert A Wild, Kevin C Maki, et al.Journal of the American Heart Association|January 15, 2013
Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trialJeremiah Stamler, James D Neaton, Jerome D Cohen, et al.The American Journal of Cardiology|September 26, 2006
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST])Rhonda Cooper-Dehoff, Jerome D Cohen, George L Bakris, et al.American Heart Journal|July 29, 2008
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudySripal Bangalore, Franz H Messerli, Jerome D Cohen, et al.Journal of Clinical Lipidology|May 23, 2019
The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapyTerry A Jacobson, Mary Katherine Cheeley, Peter H Jones, et al.The New England Journal of Medicine|April 22, 2005
Azithromycin for the secondary prevention of coronary eventsJ Thomas Grayston, Richard A Kronmal, Lisa A Jackson, et al.JAMA|December 6, 2003
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trialCarl J Pepine, Eileen M Handberg, Rhonda M Cooper-DeHoff, et al.Pageof 4